Boston Scientific Paclitaxel Stent Restenosis Rate Is Zero At Six Months
This article was originally published in The Gray Sheet
Executive Summary
Results of a 61-patient, three-center German study of Boston Scientific's paclitaxel-coated NIRx coronary stent appear to match the high standards established in recently released drug-coated stent studies sponsored by Johnson & Johnson/Cordis and Cook.
You may also be interested in...
Boston Scientific, Medinol Coronary Stent IDE Approvals Precede Legal Duel
Medinol's April 2001 lawsuit alleging Boston Scientific's development of the Express stent constitutes a breach of contract will likely be heard in New York federal court by late summer
Boston Scientific, Medinol Coronary Stent IDE Approvals Precede Legal Duel
Medinol's April 2001 lawsuit alleging Boston Scientific's development of the Express stent constitutes a breach of contract will likely be heard in New York federal court by late summer
Drug-Coated Stent Pivotal Study Will Show Improved TVR Rates, Cook Says
Cook's 1,200-patient, six-center U.S. pivotal trial (PATENCY) evaluating the Logic PTX paclitaxel-coated stent in treating de novo lesions should complete enrollment in early 2002.